Cargando…
Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety
OBJECTIVE: To investigate clinical benefit and safety of neoadjuvant chemotherapy (NAC) plus bevacizumab combined with total mesorectal excision (TME) in treating patients with BRAF-mutated locally advanced rectal cancer (LARC). METHODS: This study included LARC patients with BRAF mutation admitted...
Autores principales: | Song, Jintian, Wang, Yi, Yu, Hui, Zheng, Liang, Cai, Xiongchao, Chen, Yigui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677386/ https://www.ncbi.nlm.nih.gov/pubmed/34925539 http://dx.doi.org/10.1155/2021/4227650 |
Ejemplares similares
-
Timing of additional neoadjuvant chemotherapy in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy and total mesorectal excision
por: He, Fang, et al.
Publicado: (2022) -
Impact of neoadjuvant treatment on total mesorectal excision for ultra-low rectal cancers
por: Lim, Yon Kuei, et al.
Publicado: (2010) -
Total mesorectal excision for the treatment of rectal cancer
por: Zedan, Ali, et al.
Publicado: (2015) -
Association of Transanal Total Mesorectal Excision With Local Recurrence of Rectal Cancer
por: Caycedo-Marulanda, Antonio, et al.
Publicado: (2021) -
Robotic total mesorectal excision for the treatment of rectal cancer
por: Baik, Seung Hyuk, et al.
Publicado: (2007)